Vimarsana
Biggest News Aggregation in the World

Paradigm Diagnostics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Paradigm Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Paradigm Diagnostics Today - Breaking & Trending Today

Exact Sciences Announces Second Quarter 2022 Results - Vimarsana News

Exact Sciences Announces Second Quarter 2022 Results

Second quarter highlights Total second quarter revenue of $522 million, including Screening revenue of $354 million, Precision Oncology revenue of $154...

OSF Ventures ready to tap third and largest fund under new leadership - Vimarsana News

OSF Ventures ready to tap third and largest fund under new leadership

Mayank Taneja transitions into lead position at OSF Ventures  PEORIA, Ill., June 30, 2022 /PRNewswire/ -- OSF Ventures, the corporate investment a...

How to Support Your Muslim Coworkers Who Are Fasting During Ramadan - Vimarsana News

How to Support Your Muslim Coworkers Who Are Fasting During Ramadan

Here's what to know to make sure you don't say the wrong thing to a Muslim colleague who is observing Ramadan.

Exact Sciences Corp. acquires Marshfield-based genetic testing lab for $190 million - Vimarsana News

Exact Sciences Corp. acquires Marshfield-based genetic testing lab for $190 million

Exact Sciences Corp. has acquired Marshfield-based genetic testing laboratory PreventionGenetics for $190 million.

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights - Vimarsana News

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights

Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights News provided by Share this article SAN DIEGO, Feb. 25, 2021 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. "Over the last severa...